Literature DB >> 30552520

Rational combination of cancer immunotherapy in melanoma.

Mario Mandalà1, Piotr Rutkowski2.   

Abstract

The recent advances in cancer immunotherapy with unprecedented success in therapy of advanced melanoma represent a turning point in the landscape of melanoma treatment. Given the complexity of activation of immunological system and the physiologic multifactorial homeostatic mechanisms controlling immune responses, combinatorial strategies are eagerly needed in melanoma therapy. Nevertheless, rational selection of immunotherapy combinations should be more biomarker-guided, including not only the cancer immunogram, PD-L1 expression, interferon gene expression signature, mutational burden, and tumor infiltration by CD8+ T cells but also intratumoral T cell exhaustion and microbiota composition. In this review, we summarize the rationale to develop combination treatment strategies in melanoma and discuss biological background that could help to design new combinations in order to improve patients' outcome.

Entities:  

Keywords:  Combination; Immunotherapy; Melanoma; Outcome; Therapy

Mesh：

Substances：

Year:  2018        PMID： 30552520     DOI： 10.1007/s00428-018-2506-y

Source DB:  PubMed          Journal:  Virchows Arch        ISSN： 0945-6317            Impact factor:   4.535


  73 in total

1.  Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

Authors:  Alexander M M Eggermont; Christian U Blank; Mario Mandala; Georgina V Long; Victoria Atkinson; Stéphane Dalle; Andrew Haydon; Mikhail Lichinitser; Adnan Khattak; Matteo S Carlino; Shahneen Sandhu; James Larkin; Susana Puig; Paolo A Ascierto; Piotr Rutkowski; Dirk Schadendorf; Rutger Koornstra; Leonel Hernandez-Aya; Michele Maio; Alfonsus J M van den Eertwegh; Jean-Jacques Grob; Ralf Gutzmer; Rahima Jamal; Paul Lorigan; Nageatte Ibrahim; Sandrine Marreaud; Alexander C J van Akkooi; Stefan Suciu; Caroline Robert
Journal:  N Engl J Med       Date:  2018-04-15       Impact factor: 91.245

2.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.

Authors:  Stefani Spranger; Riyue Bao; Thomas F Gajewski
Journal:  Nature       Date:  2015-05-11       Impact factor: 49.962

Review 3.  PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux.

Authors:  Jake S O'Donnell; Daniela Massi; Michele W L Teng; Mario Mandala
Journal:  Semin Cancer Biol       Date:  2017-05-02       Impact factor: 15.707

4.  First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.

Authors:  Gregory L Beatty; Peter J O'Dwyer; Jason Clark; Jack G Shi; Kevin J Bowman; Peggy A Scherle; Robert C Newton; Richard Schaub; Janet Maleski; Lance Leopold; Thomas F Gajewski
Journal:  Clin Cancer Res       Date:  2017-01-04       Impact factor: 12.531

5.  Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients.

Authors:  Daniela Massi; Emanuela Romano; Eliana Rulli; Barbara Merelli; Romina Nassini; Francesco De Logu; Ivan Bieche; Gianna Baroni; Laura Cattaneo; Gongda Xue; Mario Mandalà
Journal:  Eur J Cancer       Date:  2017-04-14       Impact factor: 9.162

6.  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

Authors:  Jeffrey Weber; Mario Mandala; Michele Del Vecchio; Helen J Gogas; Ana M Arance; C Lance Cowey; Stéphane Dalle; Michael Schenker; Vanna Chiarion-Sileni; Ivan Marquez-Rodas; Jean-Jacques Grob; Marcus O Butler; Mark R Middleton; Michele Maio; Victoria Atkinson; Paola Queirolo; Rene Gonzalez; Ragini R Kudchadkar; Michael Smylie; Nicolas Meyer; Laurent Mortier; Michael B Atkins; Georgina V Long; Shailender Bhatia; Celeste Lebbé; Piotr Rutkowski; Kenji Yokota; Naoya Yamazaki; Tae M Kim; Veerle de Pril; Javier Sabater; Anila Qureshi; James Larkin; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2017-09-10       Impact factor: 91.245

7.  NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.

Authors:  Deborah H Charych; Ute Hoch; John L Langowski; Steve R Lee; Murali K Addepalli; Peter B Kirk; Dawei Sheng; Xiaofeng Liu; Paul W Sims; Laurie A VanderVeen; Cherie F Ali; Thomas K Chang; Marina Konakova; Rhoneil L Pena; Rupesh S Kanhere; Yolanda M Kirksey; Chunmei Ji; Yujun Wang; Jicai Huang; Theresa D Sweeney; Seema S Kantak; Stephen K Doberstein
Journal:  Clin Cancer Res       Date:  2016-02-01       Impact factor: 12.531

Review 8.  The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.

Authors:  Jedd D Wolchok; Yvonne Saenger
Journal:  Oncologist       Date:  2008

9.  The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα.

Authors:  Michael P Smith; Berta Sanchez-Laorden; Kate O'Brien; Holly Brunton; Jennifer Ferguson; Helen Young; Nathalie Dhomen; Keith T Flaherty; Dennie T Frederick; Zachary A Cooper; Jennifer A Wargo; Richard Marais; Claudia Wellbrock
Journal:  Cancer Discov       Date:  2014-10       Impact factor: 39.397

10.  Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

Authors:  Shohei Koyama; Esra A Akbay; Yvonne Y Li; Grit S Herter-Sprie; Kevin A Buczkowski; William G Richards; Leena Gandhi; Amanda J Redig; Scott J Rodig; Hajime Asahina; Robert E Jones; Meghana M Kulkarni; Mari Kuraguchi; Sangeetha Palakurthi; Peter E Fecci; Bruce E Johnson; Pasi A Janne; Jeffrey A Engelman; Sidharta P Gangadharan; Daniel B Costa; Gordon J Freeman; Raphael Bueno; F Stephen Hodi; Glenn Dranoff; Kwok-Kin Wong; Peter S Hammerman
Journal:  Nat Commun       Date:  2016-02-17       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.